Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Lumen Bio reports positive Phase 2 results for oral C. diff drug LMN-201

Lumen Bio reports positive Phase 2 results for oral C. diff drug LMN-201

New Capabilities

LMN-201 cut recurrence to 9.1% versus 55.6% with placebo in the RePreve trial

Today: Phase 2 Part B results reported

Overview

Updated 1 hour ago

C. difficile infection recurs in roughly a quarter of treated patients, sending many back to the hospital for repeat rounds of antibiotics. Lumen Bioscience's oral biologic LMN-201 cut that recurrence to 9.1% in a randomized Phase 2 trial, versus 55.6% for placebo.

The gap produced a global cure rate, meaning initial cure plus no recurrence, of 83.3% for LMN-201 versus 36.4% for placebo. The capsules, made from engineered spirulina, neutralize C. diff toxins without wiping out the gut the way antibiotics do.

Why it matters

If LMN-201 works at scale, it could break the cycle of recurrent C. diff infections that sends patients back to hospitals each year.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

83.3%
Global cure with LMN-201 (Part B)
Initial cure plus no recurrence; 10 of 12 patients versus 4 of 11 on placebo.
9.1%
C. diff recurrence with LMN-201
Compared with 55.6% for placebo, a roughly six-fold reduction.
8.75
Odds ratio for global cure
Statistically significant under the prespecified Bayesian analysis plan.
23
Patients in randomized Part B cohort
Small sample; independent observers caution the effect size is uncertain.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

CM
Carl Mason, MD
Vice President of Clinical, Lumen Bioscience
Presented RePreve results at IDWeek 2026
KK
Kole Krieger
Senior Vice President of Business Development, Lumen Bioscience
Leading commercial strategy for LMN-201

Organizations Involved

Lumen Bioscience
Lumen Bioscience
Biotechnology company
Phase 2 results reported; pivotal cohort ongoing

Seattle biotech developing oral protein therapeutics grown in engineered spirulina.

Timeline

December 2021 October 2026

5 events Latest: Today
Tap a bar to jump to that date

  1. Phase 2 Part B results reported

    Today Clinical Trial

    Global cure 83.3% with LMN-201 versus 36.4% placebo; recurrence 9.1% versus 55.6%. Presented at IDWeek 2026.

  2. Trial timelines extended

    Clinical Trial

    Registry shows primary completion moved to June 2027 and study end to December 2027.

  3. Lumen expands board and leadership

    Corporate

    New funding and executives support late-stage clinical programs and commercial readiness for LMN-201.

  4. Sentinel cohort hits 100% initial cure

    Clinical Trial

    21 of 21 RePreve sentinel patients achieved initial clinical cure; 95.2% sustained cure at four weeks.

  5. LMN-201 preclinical data posted

    Research

    bioRxiv preprint describes the spirulina platform, synthetic avidity design, and rodent challenge results.

Scenarios

1

LMN-201 moves into a pivotal Phase 3 trial

Likely Resolves by Q2 2028

Discussed by: Lumen Bioscience; clinical observers following the RePreve program

With positive Part B data, Lumen is expected to launch the larger pivotal cohort described under the RePreve protocol. The company has said it is gearing up for late-stage work and commercial readiness. A registry entry notes the study currently runs to late 2027.

2

Pivotal cohort fails to confirm the recurrence reduction

Possible Resolves by End of 2028

Discussed by: pharmacally.com and independent clinicians citing the 23-patient sample

The Part B result rests on a small sample, and recurrence is a noisy endpoint. A larger pivotal cohort would test whether the effect holds under more typical enrollment, where the placebo rate may differ from the 55.6% observed here.

3

LMN-201 wins FDA approval as a first-in-class oral biologic

Uncertain Resolves by End of 2030

Discussed by: Industry analysts tracking oral biologic approvals

The full approval path, with a successful Phase 3 and a BLA filing, would make LMN-201 one of the first cocktail biologics delivered orally. Lumen would compete with IV bezlotoxumab and oral microbiome products like Vowst for the recurrence-prevention market.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2016

Bezlotoxumab (Zinplava, 2016)

FDA approved bezlotoxumab, an IV monoclonal antibody that neutralizes C. diff toxin B, to prevent recurrence in high-risk adults. Its Phase 3 MODIFY I and II trials enrolled over 1,500 patients and set the benchmark for immunotherapy in this disease.

Then

Approved as an add-on to standard antibiotics, marketed as Zinplava.

Now

Established that targeting toxins can prevent recurrence, but IV infusion limits where and how often it is used.

Why this matters now

LMN-201 is benchmarked directly against the MODIFY I/II results, aiming to match or beat them with an oral capsule instead of an infusion.

2023

Vowst (fecal microbiota spores, 2023)

FDA approved Vowst, an oral therapeutic made from purified fecal microbiota spores, for preventing recurrent C. diff after antibiotic treatment. It was the first oral microbiome drug cleared for this indication.

Then

Gave clinicians a pill-based option for recurrence prevention.

Now

Showed oral prevention is feasible; placebo recipients in its Phase 3 still had 38% to 46% eight-week recurrence rates.

Why this matters now

Vowst defined the oral C. diff prevention market LMN-201 wants to enter, and its high placebo recurrence rates underline the need LMN-201 targets.

Sources

(8)
+2
PR Newswire Pharmacally Lumen Bioscience AdisInsight bioRxiv Drug Discovery Trends Lumen Bioscience Lumen Bioscience